Efficacy and safety of lenalidomide for refractory cutaneous lupus erythematosus

被引:0
作者
Josefina Cortés-Hernández
Gabriela Ávila
Miquel Vilardell-Tarrés
Josep Ordi-Ros
机构
[1] Hospital Universitari Vall d'Hebron,Medicine Department, Systemic Autoimmune Diseases Unit
[2] Institut de Recerca (VHIR),undefined
[3] Universitat Autònoma de Barcelona,undefined
来源
Arthritis Research & Therapy | / 14卷
关键词
Systemic Lupus Erythematosus; Thalidomide; Lenalidomide; Systemic Lupus Erythematosus Disease Activity Index; Cutaneous Lupus Erythematosus;
D O I
暂无
中图分类号
学科分类号
摘要
引用
收藏
相关论文
共 216 条
[1]  
Lee HJ(2006)Cutaneous lupus erythematosus: understanding of clinical features, genetic basis, and pathobiology of disease guides therapeutic strategies Autoimmunity 39 433-444
[2]  
Sinha AA(1981)Distinctive cutaneous subsets in the spectrum of lupus erythematosus J Am Acad Dermatol 4 471-475
[3]  
Gilliam JN(2001)The cutaneous pathology of lupus erythematosus: a review J Cutan Pathol 28 1-23
[4]  
Sontheimer RD(2011)Cutaneous lupus erythematosus: update of therapeutic options Part I J Am Acad Dermatol 65 e179-193
[5]  
Crowson AN(2005)Management of 'refractory' skin disease in patients with lupus erythematosus Best Pract Res Clin Rheumatol 19 767-784
[6]  
Magro C(2011)Cutaneous lupus erythematosus: update of therapeutic options Part II J Am Acad Dermatol 65 e195-213
[7]  
Kuhn A(1962)The saga of thalidomide. Neuropathy to embriopathy, with case reports of congenital abnormalities N Engl J Med 267 1184-1192
[8]  
Ruland V(2005)Thalidomide: dermatological indications, mechanisms of action and side-effects Br J Dermatol 153 254-273
[9]  
Bonsmann G(2003)Low-dose thalidomide therapy for refractory cutaneous lesions of lupus erythematosus Arch Dermatol 139 50-54
[10]  
Callen JP(2000)Experience with low-dose thalidomide therapy in chronic discoid lupus erythematosus Int J Dermatol 39 218-222